Bristol Myers Squibb (CGT Mfg) vs Pharmaron Biologics: CDMO Comparison
How does Bristol Myers Squibb (CGT Mfg) compare to Pharmaron Biologics for Cell & Gene Therapy manufacturing?
Side-by-side comparison of Bristol Myers Squibb (CGT Mfg) and Pharmaron Biologics on independent FDA inspections, EMA and MHRA GMP certificates, clinical-program activity, and CDMO Signal Score. Data sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.
Key differences
- Both maintain clean enforcement records — no FDA OAI classifications or warning letters on file for either CDMO.
- Bristol Myers Squibb (CGT Mfg) holds 1 active EMA GMP certificates; Pharmaron Biologics does not appear in EudraGMDP.
- Bristol Myers Squibb (CGT Mfg) maintains 1 MHRA / UK GMP certificate; Pharmaron Biologics does not.
- Bristol Myers Squibb (CGT Mfg) appears as a manufacturing partner on more matched clinical programs (584 vs 0) — a broader sponsor book.
On a 13-modality CDMO landscape, both Bristol Myers Squibb (CGT Mfg) and Pharmaron Biologics qualify as Cell & Gene Therapy manufacturers; Bristol Myers Squibb (CGT Mfg) carries the higher composite Signal Score for Cell & Gene Therapy programs in this comparison.
What to evaluate for Cell & Gene Therapy programs
Both Bristol Myers Squibb (CGT Mfg) and Pharmaron Biologics qualify as Cell & Gene Therapy CDMOs. When choosing between them for Cell & Gene Therapy programs, weigh these four dimensions specifically — each carries through to the side-by-side scorecard above.
Integrated vs point-solution CDMO
Ex vivo cell therapy programs benefit from CDMOs handling both vector and cell processing under one roof. Point-solution CDMOs specialize deeper but add tech-transfer complexity.
Regulatory record by process class
Cell therapy and viral vector inspections are separately scoped. Verify the CDMO's inspection record on the specific process class your program will use.
Chain-of-identity + cold chain
Autologous cell therapy demands per-patient scheduling, batch-of-one tracking, and cold-chain logistics that CDMOs vary meaningfully on. Confirm the CDMO's chain-of-identity software and cryopreservation posture.
Commercial track record
For late-stage programs, CDMOs with commercial-approved cell or gene therapy products on file carry demonstrable posture that ranking algorithms only partially capture.
Frequently asked: Bristol Myers Squibb (CGT Mfg) vs Pharmaron Biologics
How does Bristol Myers Squibb (CGT Mfg) compare to Pharmaron Biologics for Cell & Gene Therapy manufacturing?
On CDMO Signal's composite Signal Score, Bristol Myers Squibb (CGT Mfg) is 91/100 and Pharmaron Biologics is 87/100; Bristol Myers Squibb (CGT Mfg) has 6 FDA inspections on record vs 3 for Pharmaron Biologics; European coverage is 2 active EMA+MHRA certificates for Bristol Myers Squibb (CGT Mfg) vs 0 for Pharmaron Biologics. Both are tracked in the CDMO Signal directory as Cell & Gene Therapy CDMOs. The scorecard above breaks down every metric side by side — use it alongside each CDMO's individual profile for the full regulatory and clinical footprint.
Which has the stronger FDA inspection record, Bristol Myers Squibb (CGT Mfg) or Pharmaron Biologics?
Both Bristol Myers Squibb (CGT Mfg) and Pharmaron Biologics maintain clean enforcement records on file — no FDA warning letters and no OAI classifications. Bristol Myers Squibb (CGT Mfg) has 6 FDA inspections on record; Pharmaron Biologics has 3.
How do Bristol Myers Squibb (CGT Mfg) and Pharmaron Biologics compare on European GMP coverage?
Bristol Myers Squibb (CGT Mfg) holds 1 active EMA GMP certificate and 1 MHRA / UK certificate. Pharmaron Biologics holds 0 active EMA GMP certificates and 0 MHRA / UK certificates. Use these counts as a proxy for the breadth of each CDMO's European regulatory footprint.
Which is more active in clinical-stage manufacturing — Bristol Myers Squibb (CGT Mfg) or Pharmaron Biologics?
Bristol Myers Squibb (CGT Mfg) is matched to 584 ClinicalTrials.gov records as a manufacturing partner; Pharmaron Biologics is matched to 0. Higher counts indicate broader sponsor exposure but say nothing about approved-product track record — pair this number with each CDMO's profile page for context.
Which is better for Cell & Gene Therapy manufacturing — Bristol Myers Squibb (CGT Mfg) or Pharmaron Biologics?
Both Bristol Myers Squibb (CGT Mfg) and Pharmaron Biologics are tagged as Cell & Gene Therapy CDMOs in our directory, so both are credible options for Cell & Gene Therapy programs. The most important differentiator for Cell & Gene Therapy selection is typically integrated vs point-solution cdmo: Ex vivo cell therapy programs benefit from CDMOs handling both vector and cell processing under one roof. Point-solution CDMOs specialize deeper but add tech-transfer complexity. Review each CDMO's profile and inspection record before shortlisting.
Use the free AI matchmaker to weigh both against your specific requirements — capacity, modality, regulatory record, geography — and surface other qualified options.
Find & compare CDMOs →